查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947933

个人化癌症治疗市场分析及预测（至2035年）：按类型、产品、服务、技术、适应症、最终用户、实施类型、阶段和解决方案划分

Personalized Cancer Therapies Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, End User, Deployment, Stage, Solutions
出版日期: | 出版商: Global Insight Services | 英文 312 Pages | 商品交期: 3-5个工作天内

价格
简介目录

个人化癌症治疗市场预计将从2024年的475亿美元成长到2034年的1,078亿美元，复合年增长率约为9.1%。个人化癌症治疗市场是指根据个别基因谱量身定制治疗方法，从而提高疗效并最大限度地减少副作用。该市场整合了基因组学、生物技术和先进的诊断技术，以开发标靶治疗。随着精准医疗的日益普及，改善患者预后和提高医疗效率的需求正在推动生物标记发现、标靶药物和伴随诊断等领域的创新发展。

在基因组学和标靶治疗方法进步的推动下，个人化癌症治疗市场正在快速发展。免疫疗法领域成长最为迅猛，主要得益于查核点抑制剂和CAR-T细胞疗法的成功。这些治疗方法利用人体自身的免疫系统攻击癌细胞，正在革新癌症治疗。标靶治疗是成长第二快的领域，其中激酶抑制剂和单株抗体可根据基因谱提供精准的治疗方案。精准医疗根据个别基因标记量身订做治疗方案，正蓬勃发展，并不断提升个人化癌症治疗的疗效。伴随诊断能够深入了解患者的个人化治疗反应，对于优化治疗效果至关重要。人工智慧在药物发现和开发中的应用进一步加速了该市场的发展。随着个人化治疗方案日趋完善，以患者为中心的护理理念有望推动癌症治疗策略的持续成长和创新。

市场区隔
类型 单株抗体、细胞疗法、基因疗法、癌症疫苗、溶瘤病毒疗法、标靶小分子化合物
产品 生物製药、生物相似药、小分子药物、诊断试剂、伴随诊断试剂
服务 基因组分析、生物标记检测、免疫疗法服务、临床试验服务、咨询服务
科技 次世代定序、聚合酵素链锁反应、质谱分析、流式细胞技术、奈米技术、CRISPR
适应症 乳癌、肺癌、结肠癌、摄护腺癌、黑色素瘤、白血病
最终用户 医院、癌症研究中心、生技公司、製药公司、学术机构
实施表格 本机部署、云端部署、混合式部署
步 研究与开发、临床试验、商业化和上市后监测
解决方案 治疗、诊断和预测解决方案

个人化癌症治疗市场正经历动态变化，各种新产品的推出拓展了治疗选择。市场占有率的成长主要主导创新治疗方法，这些疗法承诺根据每位患者独特的基因谱量身定制个人化治疗方法。定价策略也在不断演变，以体现这些治疗方法的高端特性及其显着改善患者预后的潜力。该市场竞争异常激烈，各大製药公司都在研发方面投入大量资金以保持竞争优势。竞争基准分析揭示了竞争格局，主要企业不断创新以维持自身优势。监管影响至关重要，严格的指导方针规范着个人化疗法的核准和商业化。北美和欧洲等关键地区的政策制定者正积极致力于制定影响市场动态的法规结构。分析结果表明，基因组学和生物技术的进步以及对精准医疗日益增长的重视正在推动市场扩张。竞争、监管和创新之间的相互作用决定了相关人员在这个快速成长领域中的策略视角。

主要趋势和驱动因素：

个人化癌症治疗市场正经历强劲成长，这主要得益于基因组学和生物技术的进步。一个关键趋势是精准医疗方法的日益普及，该方法根据个体的基因谱量身定制治疗方法。这种转变提高了治疗效果，最大限度地减少了副作用，并显着改善了患者的预后。另一个趋势是将人工智慧 (AI) 和机器学习融入药物发现和开发过程。这些技术正在加速识别新的标靶并优化治疗方案。此外，液态生物检体技术的兴起彻底改变了癌症诊断，实现了对肿瘤动态和治疗反应的非侵入性监测。推动这一市场成长的因素包括癌症发病率的上升以及对以患者为中心的医疗保健模式的日益重视。监管机构也透过加快核准流程来支持个人化治疗。我们相信，对于那些利用最尖端科技并与学术和临床研究机构合作开发创新治疗方法的公司而言，存在着许多机会。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章 细分市场分析

  • 市场规模及预测：依类型
    • 单株抗体
    • 细胞疗法
    • 基因治疗
    • 癌症疫苗
    • 溶瘤病毒疗法
    • 标靶小分子化合物
  • 市场规模及预测：依产品划分
    • 生物製药
    • 生物相似药
    • 小分子药物
    • 诊断试剂
    • 伴随诊断
  • 市场规模及预测：依服务划分
    • 基因组分析
    • 生物标记检测
    • 免疫疗法服务
    • 临床试验服务
    • 咨询服务
  • 市场规模及预测：依技术划分
    • 次世代定序
    • 聚合酵素链锁反应
    • 质谱分析
    • 流式细胞技术
    • 奈米科技
    • CRISPR
  • 市场规模及预测：依指标
    • 乳癌
    • 肺癌
    • 大肠直肠癌
    • 摄护腺癌
    • 黑色素瘤
    • 白血病
  • 市场规模及预测：依最终用户划分
    • 医院
    • 癌症研究中心
    • 生技公司
    • 製药公司
    • 学术机构
  • 市场规模及预测：依实施类型划分
    • 本地部署
    • 基于云端的
    • 杂交种
  • 市场规模及预测：依阶段划分
    • 研究与开发
    • 临床试验
    • 商业化
    • 上市后监测
  • 市场规模及预测：按解决方案划分
    • 治疗方案
    • 诊断解决方案
    • 预测解决方案

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 需求与供给差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 法规概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • Blueprint Medicines
  • Adaptive Biotechnologies
  • Nant Health
  • G1 Therapeutics
  • C4 Therapeutics
  • Mirati Therapeutics
  • Relay Therapeutics
  • Immuno Gen
  • Harpoon Therapeutics
  • Cellectis
  • Iovance Biotherapeutics
  • Zymeworks
  • Repare Therapeutics
  • Arcus Biosciences
  • Black Diamond Therapeutics
  • Neoleukin Therapeutics
  • Fate Therapeutics
  • Allogene Therapeutics
  • Surface Oncology
  • Kura Oncology

第九章：关于我们

简介目录
Product Code: GIS32901

Personalized Cancer Therapies Market is anticipated to expand from $47.5 billion in 2024 to $107.8 billion by 2034, growing at a CAGR of approximately 9.1%. The Personalized Cancer Therapies Market encompasses treatments tailored to individual genetic profiles, enhancing efficacy and minimizing side effects. This market integrates genomics, biotechnology, and advanced diagnostics to develop targeted therapies. As precision medicine gains traction, demand is rising for innovations in biomarker discovery, targeted drugs, and companion diagnostics, driven by the quest for improved patient outcomes and healthcare efficiency.

The Personalized Cancer Therapies Market is evolving rapidly, propelled by advances in genomics and targeted treatment approaches. The immunotherapy segment is the top performer, driven by the success of checkpoint inhibitors and CAR-T cell therapies. These therapies are revolutionizing cancer treatment by harnessing the body's immune system to attack cancer cells. Targeted therapy follows as the second highest performing segment, with kinase inhibitors and monoclonal antibodies offering precise treatment options based on genetic profiles. Precision medicine, which tailors treatment to individual genetic markers, is gaining momentum, enhancing the efficacy of personalized cancer therapies. Companion diagnostics are crucial, providing insights into patient-specific treatment responses and optimizing therapeutic outcomes. The integration of artificial intelligence in drug discovery and development is further accelerating advancements in this market. As personalized approaches become more refined, the focus on patient-centric care is expected to drive continued growth and innovation in cancer treatment strategies.

Market Segmentation
TypeMonoclonal Antibodies, Cell Therapy, Gene Therapy, Cancer Vaccines, Oncolytic Virus Therapy, Targeted Small Molecules
ProductBiologics, Biosimilars, Small Molecule Drugs, Diagnostics, Companion Diagnostics
ServicesGenomic Profiling, Biomarker Testing, Immunotherapy Services, Clinical Trial Services, Consulting Services
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Mass Spectrometry, Flow Cytometry, Nanotechnology, CRISPR
ApplicationBreast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Leukemia
End UserHospitals, Cancer Research Centers, Biotechnology Companies, Pharmaceutical Companies, Academic Institutions
DeploymentOn-premise, Cloud-based, Hybrid
StageResearch and Development, Clinical Trials, Commercialization, Post-Market Surveillance
SolutionsTherapeutic Solutions, Diagnostic Solutions, Predictive Solutions

The Personalized Cancer Therapies Market is witnessing a dynamic shift with a diverse range of new product launches enhancing treatment options. Market share is dominated by innovative therapies that promise tailored treatment regimens, aligning with patient-specific genetic profiles. Pricing strategies are evolving, reflecting the premium nature of these therapies and their potential to significantly improve patient outcomes. The market is characterized by robust competition, with major pharmaceutical companies investing heavily in research and development to maintain a competitive edge. Competition benchmarking reveals a landscape where leading firms are continuously innovating to stay ahead. Regulatory influences are pivotal, with stringent guidelines governing the approval and commercialization of personalized therapies. Policymakers in key regions like North America and Europe are actively shaping the regulatory framework, impacting market dynamics. Analytical insights indicate a growing emphasis on precision medicine, with advancements in genomics and biotechnology driving market expansion. The interplay of competition, regulation, and innovation defines the strategic outlook for stakeholders in this burgeoning field.

Geographical Overview:

The personalized cancer therapies market is witnessing robust growth across various regions, each presenting unique opportunities. North America leads the charge, driven by cutting-edge research and substantial investment in precision medicine. The presence of leading biotechnology firms and advanced healthcare infrastructure further bolsters this region's dominance. Europe follows, with strong government support and a growing emphasis on personalized healthcare solutions. The region's commitment to innovation and patient-centric approaches enhances its market potential. In Asia Pacific, the market is expanding rapidly, propelled by rising cancer prevalence and increasing healthcare expenditure. Countries like China and India are emerging as key growth pockets due to their large patient populations and improving healthcare systems. Meanwhile, Latin America and the Middle East & Africa are gaining traction as emerging markets. In Latin America, initiatives to improve healthcare access and infrastructure are driving market growth. The Middle East & Africa are recognizing the potential of personalized therapies to address unmet medical needs, presenting lucrative opportunities for market expansion.

The personalized cancer therapies market is navigating a landscape shaped by global tariffs, geopolitical tensions, and evolving supply chain dynamics. In Japan and South Korea, trade tensions with major economies are fostering investments in local biotech innovation to mitigate dependency on foreign technologies. China's strategic pivot towards self-sufficiency is accelerating its development of domestic biopharmaceutical capabilities, while Taiwan's robust biotech sector remains vulnerable to geopolitical uncertainties. Globally, the parent market is experiencing robust growth, driven by advancements in precision medicine and genomic research. By 2035, the market's trajectory will hinge on resilient supply chains and cross-border collaborations. Meanwhile, Middle East conflicts could exacerbate global supply chain disruptions and elevate energy prices, influencing manufacturing costs and distribution strategies within the sector.

Key Trends and Drivers:

The personalized cancer therapies market is experiencing robust growth, driven by advances in genomics and biotechnology. Key trends include the increasing adoption of precision medicine approaches, which tailor treatments based on individual genetic profiles. This shift is enhancing treatment efficacy and minimizing adverse effects, significantly improving patient outcomes. Another trend is the integration of artificial intelligence and machine learning in drug discovery and development processes. These technologies are accelerating the identification of novel targets and optimizing treatment regimens. Furthermore, the rise of liquid biopsy techniques is revolutionizing cancer diagnostics, enabling non-invasive monitoring of tumor dynamics and treatment responses. Drivers include a growing prevalence of cancer and a heightened focus on patient-centric healthcare models. Regulatory bodies are also supporting personalized therapies through expedited approval pathways. Opportunities abound for companies that leverage cutting-edge technologies and collaborate with academic and clinical research institutions to develop innovative treatments.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by End User
  • 2.7 Key Market Highlights by Deployment
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Solutions

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Monoclonal Antibodies
    • 4.1.2 Cell Therapy
    • 4.1.3 Gene Therapy
    • 4.1.4 Cancer Vaccines
    • 4.1.5 Oncolytic Virus Therapy
    • 4.1.6 Targeted Small Molecules
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Biologics
    • 4.2.2 Biosimilars
    • 4.2.3 Small Molecule Drugs
    • 4.2.4 Diagnostics
    • 4.2.5 Companion Diagnostics
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genomic Profiling
    • 4.3.2 Biomarker Testing
    • 4.3.3 Immunotherapy Services
    • 4.3.4 Clinical Trial Services
    • 4.3.5 Consulting Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Mass Spectrometry
    • 4.4.4 Flow Cytometry
    • 4.4.5 Nanotechnology
    • 4.4.6 CRISPR
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Breast Cancer
    • 4.5.2 Lung Cancer
    • 4.5.3 Colorectal Cancer
    • 4.5.4 Prostate Cancer
    • 4.5.5 Melanoma
    • 4.5.6 Leukemia
  • 4.6 Market Size & Forecast by End User (2020-2035)
    • 4.6.1 Hospitals
    • 4.6.2 Cancer Research Centers
    • 4.6.3 Biotechnology Companies
    • 4.6.4 Pharmaceutical Companies
    • 4.6.5 Academic Institutions
  • 4.7 Market Size & Forecast by Deployment (2020-2035)
    • 4.7.1 On-premise
    • 4.7.2 Cloud-based
    • 4.7.3 Hybrid
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Research and Development
    • 4.8.2 Clinical Trials
    • 4.8.3 Commercialization
    • 4.8.4 Post-Market Surveillance
  • 4.9 Market Size & Forecast by Solutions (2020-2035)
    • 4.9.1 Therapeutic Solutions
    • 4.9.2 Diagnostic Solutions
    • 4.9.3 Predictive Solutions

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 End User
      • 5.2.1.7 Deployment
      • 5.2.1.8 Stage
      • 5.2.1.9 Solutions
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 End User
      • 5.2.2.7 Deployment
      • 5.2.2.8 Stage
      • 5.2.2.9 Solutions
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 End User
      • 5.2.3.7 Deployment
      • 5.2.3.8 Stage
      • 5.2.3.9 Solutions
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 End User
      • 5.3.1.7 Deployment
      • 5.3.1.8 Stage
      • 5.3.1.9 Solutions
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 End User
      • 5.3.2.7 Deployment
      • 5.3.2.8 Stage
      • 5.3.2.9 Solutions
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 End User
      • 5.3.3.7 Deployment
      • 5.3.3.8 Stage
      • 5.3.3.9 Solutions
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 End User
      • 5.4.1.7 Deployment
      • 5.4.1.8 Stage
      • 5.4.1.9 Solutions
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 End User
      • 5.4.2.7 Deployment
      • 5.4.2.8 Stage
      • 5.4.2.9 Solutions
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 End User
      • 5.4.3.7 Deployment
      • 5.4.3.8 Stage
      • 5.4.3.9 Solutions
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 End User
      • 5.4.4.7 Deployment
      • 5.4.4.8 Stage
      • 5.4.4.9 Solutions
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 End User
      • 5.4.5.7 Deployment
      • 5.4.5.8 Stage
      • 5.4.5.9 Solutions
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 End User
      • 5.4.6.7 Deployment
      • 5.4.6.8 Stage
      • 5.4.6.9 Solutions
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 End User
      • 5.4.7.7 Deployment
      • 5.4.7.8 Stage
      • 5.4.7.9 Solutions
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 End User
      • 5.5.1.7 Deployment
      • 5.5.1.8 Stage
      • 5.5.1.9 Solutions
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 End User
      • 5.5.2.7 Deployment
      • 5.5.2.8 Stage
      • 5.5.2.9 Solutions
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 End User
      • 5.5.3.7 Deployment
      • 5.5.3.8 Stage
      • 5.5.3.9 Solutions
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 End User
      • 5.5.4.7 Deployment
      • 5.5.4.8 Stage
      • 5.5.4.9 Solutions
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 End User
      • 5.5.5.7 Deployment
      • 5.5.5.8 Stage
      • 5.5.5.9 Solutions
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 End User
      • 5.5.6.7 Deployment
      • 5.5.6.8 Stage
      • 5.5.6.9 Solutions
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 End User
      • 5.6.1.7 Deployment
      • 5.6.1.8 Stage
      • 5.6.1.9 Solutions
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 End User
      • 5.6.2.7 Deployment
      • 5.6.2.8 Stage
      • 5.6.2.9 Solutions
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 End User
      • 5.6.3.7 Deployment
      • 5.6.3.8 Stage
      • 5.6.3.9 Solutions
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 End User
      • 5.6.4.7 Deployment
      • 5.6.4.8 Stage
      • 5.6.4.9 Solutions
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 End User
      • 5.6.5.7 Deployment
      • 5.6.5.8 Stage
      • 5.6.5.9 Solutions

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 Blueprint Medicines
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Adaptive Biotechnologies
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Nant Health
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 G1 Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 C4 Therapeutics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Mirati Therapeutics
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Relay Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Immuno Gen
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Harpoon Therapeutics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Cellectis
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Iovance Biotherapeutics
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Zymeworks
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Repare Therapeutics
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Arcus Biosciences
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Black Diamond Therapeutics
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Neoleukin Therapeutics
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Fate Therapeutics
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Allogene Therapeutics
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Surface Oncology
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Kura Oncology
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us